{"id":63627,"date":"2026-04-21T17:42:10","date_gmt":"2026-04-21T09:42:10","guid":{"rendered":"https:\/\/flcube.com\/?p=63627"},"modified":"2026-04-21T17:42:11","modified_gmt":"2026-04-21T09:42:11","slug":"fda-grants-priority-review-to-merck-astellas-and-pfizers-sbla-for-padcev-pembrolizumab-combo-in-perioperative-muscle-invasive-bladder-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63627","title":{"rendered":"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer"},"content":{"rendered":"\n<p><strong>Merck &amp; Co.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>), <strong>Astellas Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4503:TYO\">TYO: 4503<\/a>), and <strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has accepted for review and granted <strong>Priority Review<\/strong> to a <strong>supplemental Biologics License Application (sBLA)<\/strong> for the combination of <strong>Padcev\u00ae (enfortumab vedotin)<\/strong> and <strong>pembrolizumab<\/strong>\u2014administered either <strong>intravenously or subcutaneously<\/strong>\u2014for the <strong>perioperative (neoadjuvant and adjuvant) treatment of muscle-invasive bladder cancer (MIBC)<\/strong>. The FDA has set a <strong>Prescription Drug User Fee Act (PDUFA) action date in Q3 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-clinical-context\">Regulatory &amp; Clinical Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Current Indication (US)<\/strong><\/td><td>Approved for <strong>locally advanced or metastatic urothelial cancer (la\/mUC)<\/strong><\/td><\/tr><tr><td><strong>November 2025 Approval<\/strong><\/td><td><strong>Neoadjuvant + adjuvant<\/strong> use in <strong>cisplatin-ineligible MIBC<\/strong> patients undergoing cystectomy<\/td><\/tr><tr><td><strong>New sBLA Scope<\/strong><\/td><td><strong>Full perioperative regimen<\/strong> (pre- and post-surgery) in <strong>broader MIBC population<\/strong>, including cisplatin-eligible patients<\/td><\/tr><tr><td><strong>Review Designation<\/strong><\/td><td><strong>Priority Review<\/strong> (6-month timeline vs. standard 10 months)<\/td><\/tr><tr><td><strong>PDUFA Date<\/strong><\/td><td>Expected Q3 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profiles\">Drug Profiles<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Padcev (enfortumab vedotin)<\/strong>: Antibody-drug conjugate (ADC) targeting <strong>Nectin-4<\/strong>, a protein highly expressed in urothelial cancers<\/li>\n\n\n\n<li><strong>Pembrolizumab<\/strong>: Anti\u2013PD-1 immune checkpoint inhibitor (available IV or SC)<\/li>\n\n\n\n<li><strong>Combo Rationale<\/strong>: Synergistic mechanism\u2014ADC delivers cytotoxic payload directly to tumor cells while pembrolizumab reactivates T-cell anti-tumor immunity<\/li>\n<\/ul>\n\n\n\n<p>Muscle-invasive bladder cancer affects ~20,000 patients annually in the U.S., with <strong>radical cystectomy<\/strong> as standard care. However, <strong>&gt;50% of patients relapse<\/strong> post-surgery, highlighting the need for effective systemic perioperative therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-amp-strategic-implications\">Commercial &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion<\/strong>: If approved, the combo could become the <strong>first systemic perioperative standard of care<\/strong> for MIBC, regardless of cisplatin eligibility<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong>: No other regimen currently holds an FDA-approved perioperative indication in MIBC<\/li>\n\n\n\n<li><strong>Revenue Upside<\/strong>: Analysts estimate peak annual sales of <strong>$2.5\u20133.0 billion<\/strong> across all urothelial cancer settings by 2030<\/li>\n\n\n\n<li><strong>Global Alignment<\/strong>: U.S. approval would support similar filings in <strong>EU, Japan, and China<\/strong>, where la\/mUC indications are already active<\/li>\n<\/ul>\n\n\n\n<p>The companies are also evaluating <strong>subcutaneous pembrolizumab<\/strong> to improve patient convenience\u2014a key differentiator in outpatient oncology.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory outcomes, commercial potential, and clinical development. Actual results may differ due to FDA decisions, competitive dynamics, and real-world adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,353,16,29,38,2675,176,903,863,18,309,1177],"class_list":["post-63627","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-astellas-pharma","tag-cancer","tag-combination-therapy","tag-market-approval-filings","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-nyse-pfe","tag-pd-1-l1","tag-pfizer","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review to a supplemental Biologics License Application (sBLA) for the combination of Padcev\u00ae (enfortumab vedotin) and pembrolizumab\u2014administered either intravenously or subcutaneously\u2014for the perioperative (neoadjuvant and adjuvant) treatment of muscle-invasive bladder cancer (MIBC). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q3 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63627\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review to a supplemental Biologics License Application (sBLA) for the combination of Padcev\u00ae (enfortumab vedotin) and pembrolizumab\u2014administered either intravenously or subcutaneously\u2014for the perioperative (neoadjuvant and adjuvant) treatment of muscle-invasive bladder cancer (MIBC). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q3 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63627\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T09:42:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T09:42:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63627#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63627\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer\",\"datePublished\":\"2026-04-21T09:42:10+00:00\",\"dateModified\":\"2026-04-21T09:42:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63627\"},\"wordCount\":357,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Astellas Pharma\",\"Cancer\",\"Combination therapy\",\"Market approval filings\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"NYSE: PFE\",\"PD-1\\\/L1\",\"Pfizer\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63627#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63627\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63627\",\"name\":\"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-21T09:42:10+00:00\",\"dateModified\":\"2026-04-21T09:42:11+00:00\",\"description\":\"Merck & Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review to a supplemental Biologics License Application (sBLA) for the combination of Padcev\u00ae (enfortumab vedotin) and pembrolizumab\u2014administered either intravenously or subcutaneously\u2014for the perioperative (neoadjuvant and adjuvant) treatment of muscle-invasive bladder cancer (MIBC). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q3 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63627#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63627\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63627#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review to a supplemental Biologics License Application (sBLA) for the combination of Padcev\u00ae (enfortumab vedotin) and pembrolizumab\u2014administered either intravenously or subcutaneously\u2014for the perioperative (neoadjuvant and adjuvant) treatment of muscle-invasive bladder cancer (MIBC). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q3 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63627","og_locale":"en_US","og_type":"article","og_title":"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer","og_description":"Merck & Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review to a supplemental Biologics License Application (sBLA) for the combination of Padcev\u00ae (enfortumab vedotin) and pembrolizumab\u2014administered either intravenously or subcutaneously\u2014for the perioperative (neoadjuvant and adjuvant) treatment of muscle-invasive bladder cancer (MIBC). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q3 2026.","og_url":"https:\/\/flcube.com\/?p=63627","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-21T09:42:10+00:00","article_modified_time":"2026-04-21T09:42:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63627#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63627"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer","datePublished":"2026-04-21T09:42:10+00:00","dateModified":"2026-04-21T09:42:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63627"},"wordCount":357,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Astellas Pharma","Cancer","Combination therapy","Market approval filings","Merck Sharp &amp; Dohme","MSD","NYSE: MRK","NYSE: PFE","PD-1\/L1","Pfizer","TYO: 4503"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63627#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63627","url":"https:\/\/flcube.com\/?p=63627","name":"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-21T09:42:10+00:00","dateModified":"2026-04-21T09:42:11+00:00","description":"Merck & Co. (MSD, NYSE: MRK), Astellas Pharma (TYO: 4503), and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review to a supplemental Biologics License Application (sBLA) for the combination of Padcev\u00ae (enfortumab vedotin) and pembrolizumab\u2014administered either intravenously or subcutaneously\u2014for the perioperative (neoadjuvant and adjuvant) treatment of muscle-invasive bladder cancer (MIBC). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q3 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63627#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63627"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63627#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Grants Priority Review to Merck, Astellas, and Pfizer\u2019s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63627"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63627\/revisions"}],"predecessor-version":[{"id":63629,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63627\/revisions\/63629"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}